32nd General Annual Meeting of the Belgian Hematology Society

(9) 10-11 February 2017Dolce La Hulpe, Brussels

www.bhs.be

Final programme

BHS EVENTS APP

information on page 13!

1

SCIENTIFIC COMMITTEE - BHS BOARD MEMBERS AND FUNCTIONSFleur Samantha Benghiat Educational affairs Dimitri Breems Councilor Scientific affairs Kristel Buvé Councilor Clinical affairs Barbara Cauwelier TreasurerAnn De Becker Secretary, Master of festivities Anne De Weweire Councilor CommitteesChantal Doyen Patient affairs Ann Janssens WebsiteDominiek Mazure Transplant RegistryNathalie Meuleman PresidentCécile Springael Councilor CommitteesNicole Straetmans Clinical affairsAnn Van de Velde Nurse CommitteeMarie-Christiane Vekemans Vice presidentEvelyne Willems Educational affairs

BHS & CONGRESS SECRETARIAT

Congress CareP.O. Box 4405201 AK ’s-HertogenboschThe NetherlandsTel +31 (0)73 690 14 15bhs@congresscare.com www.congresscare.com

More Life Better Life

Every day is worth living

BE-C

ELG1

6000

6

2015-026 CELCOR Annonce Corporate NEW 240216.indd 1 24/02/16 13:02

3

INTRODUCTION

Dear colleagues,

Welcome at the 32nd General Annual Meeting of the BHS!.

The board has arranged for a high-level scientific program which covers differenthematology sub-specialties. The scientific presentations will cover new developments and current recommendations for treatment of hematological diseases, but also their diagnosis approach. Based on the success of the presentation « Cost of cancer treatments » last year, we decided to prolong this experience by creating an Ethics and Economy session that will bring up this year the topic of biosimilars. Another new session « Advances in laboratory technology» has been introduced with two presentations: the first one on minimal residual disease and the second one on next-generation sequencing. The research is once again brought to the forefront with among others the selected oral presentations, the commented poster walk and the awards for young researchers.

On Thursday February 9th, there are two events. The first one approaches an important mission of the BHS: the aid to patient organizations. After last year’s successful meeting, we are pleased to welcome anew the patient committees for interactive sessions. The second one is the reintroduction of the committees meeting. This will be a great opportunity to discover the committees activities but most importantly to benefit from their experience and promote interaction in the hematological community.

For several years the “Nurse symposium” has become a must of our meeting and it is with great enthusiasm that we will welcome them once again.

We encourage all colleagues to join us and discover this exciting program!

Nathalie MeulemanPresident BHS

Hematology

©Ja

nsse

n-Ci

lag

NV

- PH

BE/H

EM/0

216/

0001

(1) -

vu/

er E

rik P

rese

nt, A

ntw

erps

eweg

15-

17, 2

340

Beer

se

Janssen-Cilag NV

63572_Hema-TIOUP_herinner_adv_A5_BE.indd 2 02-02-17 09:23

5

NY

/ON

C/1

6/00

07 -

May

201

6

PROGRAM BHS COMMITTEE MEETING THURSDAY 9 FEBRUARY 2017

15.00 -16.15 Committee meeting part 1

Welcome Chairs: Marie-Christiane Vekemans and Nathalie Meuleman Introduction Marie-Christiane Vekemans,Vice-president Lymphoproliferative disorders Ann Janssens Myeloma Chantal Doyen Myelodysplasia Stef Meers Myeloproliferative neoplasms Timothy Devos

Red blood cell disorders Béatrice Gulbis

16.15 - 16.45 Break

16.45 - 18.00 Committee meeting part 2 Marrow donor program Etienne Baudoux Transplantation Yves Beguin Nurses committee Martine Heylens Regulatory affairs Nathalie Meuleman JACIE Ivan Van Riet 18.00 Closing remarks Marie-Christiane Vekemans, Vice-president BHS

6 7

PROGRAM GENERAL ANNUAL MEETINGFRIDAY 10 FEBRUARY 2017

Canopée Auditorium08.00 - 08.45 Registration

08.45 - 09.00 Welcome Nathalie Meuleman, President BHS

09.00 - 10.00 Highlights on rare lymphoproliferative diseases Chairs: Ann Janssens and Cécile Springael How to diagnose and treat ?09.00 Lymphomas in the immunocompromised patients Daan Dierickx, UZ Leuven09.30 Primary central nervous system lymphoma Andrés Ferreri, Milano, Italy

10.00 - 11.30 Advances in laboratory technology Chairs: Dimitri Breems and Barbara Cauwelier10.00 Next generation sequencing in Hematology Fabrice Jardin, Rouen, France 10.30 Minimal residual disease in acute myeloid leukemia Peter Valk, Erasmus UMC, Rotterdam, the Netherlands

11.00 - 11.30 Coffee break

11.30 - 12.30 Satellite session 1 sponsored by Bristol-Meyers Squibb Immuno-oncology: a new era in hematology treatment 11:30 Making progress with I-O in hematology Pierre Coulie, UCL – Ludwig Institute, Brussels12:00 PD-1 pathway blockade in classical Hodgkin Lymphoma Roch Houot, CHU de Rennes, France

12.30 - 13.30 Lunch and Commented Poster walk 1

13.30 - 15.00 Selected ORAL ABSTRACTS Chairs: Ann Van de Velde and Nicole Straetmans 13:30 A new frailty scoring in ‘clinically fit” older patients with malignant

hemopathies admitted to receive chemotherapy Stephanie Dubruille, I.J. Bordet (ULB)13:45 A single analysis for simultaneous measurement of all 4 DOACs Jan Emmerechts, AZ Sint-Jan14:00 Maternal Embryonic Leucine Zipper Kinase (MELK) drives a

high-risk gene network and represents an attractive novel drug target in Multiple Myeloma and its associated bone disease

Arnold Bolomsky, Wilhelminenspital, Vienna, Austria14:15 In vitro generation of tumor antigen-specific T cells from patient and

healthy donor stem cells Sarahm Bonte, UZ Gent14:30 Sequential administration of 5-azacytidine (AZA) and donor

lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation

Xavier Poiré, UCL Saint Luc14:45 Successful transition from paediatric to adult care in Sickle Cell

Disease: An experience in a Belgian center. Tracy Vandergraesen, Hopital Universitaire Des Enfants Reine Fabiola

15.00 - 15.30 Special lecture 1 Chairs: Kristel Buve and Evelyne Willems Myelodysplastic syndromes and the new WHO classification Gregor Verhoef, UZ Leuven

15.30 - 16.00 Coffee break

16.00 - 17.00 Pierre Stryckmans Lecture Chair: Nathalie Meuleman and Marie-Christiane Vekemans Acute promyelocytic leukemia: state of the art Francesco Lo Coco, University Tor Vergata, Roma, Italy

17.00 - 18.00 Ethics and Economy Chair: Nathalie Meuleman and Ann Janssens Biosimilars in the Belgian health care plan Maggie De Block, Federal Minister of Health, Belgium

18.00 - 19.00 Reception and commented Poster walk 2

9

PROGRAM GENERAL ANNUAL MEETINGSATURDAY 11 FEBRUARY 2017

Canopée Auditorium08.30 - 09.00 GENERAL ASSEMBLY

09.00 - 10.00 Satellite session 2 sponsored by Janssen 09.00 Treatment of Multiple myeloma in the era of monoclonal antibodies Niels van de Donk, VUMC Amsterdam, the Netherlands 09.30 Advances in the treatment of Chronic Lymphocytic Leukemia Paolo Ghia, Milano, Italy

10.00 - 10.30 Special lectures 2 Chairs: Ann De Becker and Samantha Benghiat10.00 Common variable immunodeficiency Isabelle Meyts, UZ Leuven 10.30 Stopping tyrosine kinase inhibitors in Chronic Myeloid Leukemia Delphine Rea, Paris, France Saint Louis Hospital

11.00 - 11.30 Coffee break

11.30 - 12.30 Satellite session 3 sponsored by Novartis 11.30 New insights in the treatment of Polycythemia Vera patients. Claire Harrison, Guy’s and St Thomas’ Hospital, London, UK12.00 JAK signaling in hematological malignancies, new horizons Stefan Constantinescu, Ludwig Institute, Brussels

12.30 Awards for best oral and poster presentations

CLOSING

11

R.E. A

MGEN

nv/s

a Av ;

Arian

elaan

5 –

1200

Bxl /

BL-P-

CARF

-0816

-0363

11 /

Date

of cre

ation

29 Au

g 201

6

AMG-Kyprolis Pub A5 BEL ENG (SH 8074) Portrait.indd 1 02/02/2017 11:01

PRELIMINARY PROGRAM NURSE MEETINGFRIDAY 10 FEBRUARY 2017

Baobab Auditorium09.15 Welcome

09.30-11.00 Oral therapy in hematology anno 2017: a multidisciplinary approach

09.30 The view of the hematologist Jan Van Droogenbroeck, AZ St-Jan Brugge10.10 The eye of the pharmacist Kim Herman, AZ St-Jan Brugge10.35 The role of the specialist nurse Ann Tegethoff, AZ St-Jan Brugge

11.00-11.30 Coffee break

11.30-12.30 Motivational interviewing - How to engage, activate and empower your patients Tim Anstiss, UK

12.30-13.30 Lunch and Commented Poster walk 1

13.30-14.30 ALL: Case studies Carlos Graux, CHU UCL Namur

14.30-15.30 All people are different, but some people are more different than others

Patrice Van der Taelen, member of the Committee on Medical Ethics UZLeuven

15.30-16.00 Coffee break

Baobab Auditorium16.00-16.30 Let’s Granny have a transplantation Xavier Poire UCL

Saint Luc

18.00-19.00 Reception and Commented Poster walk 2

Canopée Auditorium16.00-17.00 PIERRE STRYCKMANS

Lecture (no translation)16.10 APL Francesco Lo Coco, Roma, Italy

17.00-18.00 Biosimilars Maggie De Block

13

STRIVING TO OUTSMART CANCER. TOGETHER.

At AbbVie, we build bonds with haematologists, oncologists, patients, payers, advocacy groups, health authorities, and other pharmaceutical companies, because we know that advancing the science of this devastating disease is not something that one person, or even one company, can do alone. Together we can conduct research that deepens our understanding of the disease and its pathways, to ultimately develop new molecules that make a transformational improvement in cancer care.

people. passion. possibilities. AbbVie SA/NV - BEONC170041 - 022017

STRIVING TO OUTSMART CANCER. TOGETHER.

At AbbVie, we build bonds with haematologists, oncologists, patients, payers, advocacy groups, health authorities, and other pharmaceutical companies, because we know that advancing the science of this devastating disease is not something that one person, or even one company, can do alone. Together we can conduct research that deepens our understanding of the disease and its pathways, to ultimately develop new molecules that make a transformational improvement in cancer care.

people. passion. possibilities. AbbVie SA/NV - BEONC170041 - 022017

STRIVING TO OUTSMART CANCER. TOGETHER.

At AbbVie, we build bonds with haematologists, oncologists, patients, payers, advocacy groups, health authorities, and other pharmaceutical companies, because we know that advancing the science of this devastating disease is not something that one person, or even one company, can do alone. Together we can conduct research that deepens our understanding of the disease and its pathways, to ultimately develop new molecules that make a transformational improvement in cancer care.

people. passion. possibilities. AbbVie SA/NV - BEONC170041 - 022017

STRIVING TO OUTSMART CANCER. TOGETHER.

At AbbVie, we build bonds with haematologists, oncologists, patients, payers, advocacy groups, health authorities, and other pharmaceutical companies, because we know that advancing the science of this devastating disease is not something that one person, or even one company, can do alone. Together we can conduct research that deepens our understanding of the disease and its pathways, to ultimately develop new molecules that make a transformational improvement in cancer care.

people. passion. possibilities. AbbVie SA/NV - BEONC170041 - 022017

STRIVING TO OUTSMART CANCER. TOGETHER.

At AbbVie, we build bonds with haematologists, oncologists, patients, payers, advocacy groups, health authorities, and other pharmaceutical companies, because we know that advancing the science of this devastating disease is not something that one person, or even one company, can do alone. Together we can conduct research that deepens our understanding of the disease and its pathways, to ultimately develop new molecules that make a transformational improvement in cancer care.

people. passion. possibilities. AbbVie SA/NV - BEONC170041 - 022017

STRIVING TO OUTSMART CANCER. TOGETHER.

At AbbVie, we build bonds with haematologists, oncologists, patients, payers, advocacy groups, health authorities, and other pharmaceutical companies, because we know that advancing the science of this devastating disease is not something that one person, or even one company, can do alone. Together we can conduct research that deepens our understanding of the disease and its pathways, to ultimately develop new molecules that make a transformational improvement in cancer care.

people. passion. possibilities. AbbVie SA/NV - BEONC170041 - 022017

BHS EVENTS APP

Download instructionsThe APP can be downloaded from the App Store and Google Play store. If you have not downloaded the BHS Events App yet, you will need to download that App first.1. Download the BHS Events App2. After completion: install BHS GAM 2017 into the BHS Events App3. In case the App is already installed on your mobile device, please install the update

15

BHS CORPORATE MEMBERS & BHS GAM SPONSORS

Platinum

Gold

Silver

Bronze

Sponsors / exhibitors GAM 2017AlexionCSL BehringIncyte BiosciencesJazz PharmaceuticalsLeo PharmaMallinckrodt PharmaceuticalsSandozSanofi / GenzymeShireSOBIVifor Pharma

17

GENERAL INFORMATION

REGISTRATION FOR THE GENERAL ANNUAL MEETING 2017Registration via website www.BHS.be

BHS Member (MD hematologists, MD specialists, Senior scientists) E 100BHS Junior member (MD trainees, PhD students) E 50Non-member E 200

Nurses, lab. technicians, psychologists, data managers and quality managers:BHS Associate member - Nurse meeting only E 25BHS Associate member - GAM meeting (2 days) E 50Non Associate member - Nurse meeting only E 35Non Associate member - GAM meeting (2 days) E 70

PLEASE NOTEOnly approved 2016 BHS members are entitled to register for the GAM at the discounted BHS member registration fee. Payment of your 2016 membership fee should be settled before January 1st, 2017!

ELECTIONS OF BOARD MEMBERSOnly regular members are allowed to vote. Information on e-voting will be send to members.

ACCREDITATIONAccreditation for the General Annual Meeting is pending with specific accreditation for Ethics and Economy « lecture on biosimilars ».Accreditation will only be registered if the online survey has been completed.

EXHIBITIONA technical and pharmaceutical exhibition will be organized in conjunction with the annual meeting of the Belgian Hematology Society.

Every day counts*1-8

1 x 6 mg/0,6 ml Prijs af-fabriek/Prix ex-usine: € 1.102,75

* Lonquex is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)

References: 1 Pettengell R, et al. Support Care Cancer 2008;16:1299-309. 2 daCosta DiBonaventura M, et al. Am Health Drug Benefi ts 2014;7:386-96. 3 Teu� el O, et al. Support Care Cancer 2012;20:2755-64. 4 Fortner BV, et al. J Support Oncol 2006;4:472-8. 5 Fortner BV, et al. Support Cancer Ther 2006;3:173-7. 6 Meza L, et al. Proc Am Soc Clin Oncol 2002;21:abstract 2640. 7 Crawford J. Chapter 9. From: Cancer and Drug Discovery Development:Supportive Care in Cancer Therapy DOI: 10.1007/978-1-59745-291-5_9, Edited by: D.S. Ettinger ©Humana Press, Totowa, NJ. 8 Li Y, et al. Blood. 2014;124:abstract 4960.

▼ This medicinal product is subject to additional monitoring. This will allow quick identifi cation of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

NAME OF THE MEDICINAL PRODUCT: Lonquex 6 mg solution for injection. QUALITATIVE AND QUANTITATIVE COMPOSITION: Each pre-fi lled syringe contains 6  mg of lipegfi lgrastim* in 0.6 ml solution. Each ml of solution for injection contains 10 mg of lipegfi lgrastim. The active substance is a covalent conjugate of fi lgrastim** with me thoxy polyethylene glycol (PEG) via a carbohydrate linker. *This is based on protein content only. The concentration is 20.9  mg/ml (i.e. 12.6  mg per pre-fi lled syringe) if the PEG moiety and the carbohydrate linker are included. **Filgrastim (recombinant methionyl human granulocyte-colony stimulating factor [G-CSF]) is produced in Escherichia coli cells by recombinant DNA technology. The potency of this medicinal product should not be compared to the potency of another pegylated or non-pegylated protein of the same therapeutic class. For more information, see section 5.1. Excipients with known e� ect Each pre-fi lled syringe contains 30 mg sorbitol. Each pre-fi lled syringe contains less than 1 mmol (23 mg) sodium. For the full list of excipients, see section 6.1. PHARMACEUTICAL FORM: Solution for injection (injection). Clear, colourless solution. CLINICAL PARTICULARS: Therapeutic indications: Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Posology and method of administration: Lonquex treatment should be initiated and supervised by physicians experienced in oncology or haematology. Posology One 6 mg dose of lipegfi lgrastim (a single pre-fi lled syringe of Lonquex) is recommended for each chemotherapy cycle, given approximately 24 hours after cytotoxic chemotherapy. Special populations Elderly patients In clinical studies with a limited number of elderly patients, there was no relevant age-related di� erence with regard to the e� cacy or safety profi les of lipegfi lgrastim. Therefore, no adjustment of the dose is necessary for elderly patients. Patients with renal impairment Currently available data are described in section 5.2, but no recommendation on a posology can be made. Patients with hepatic impairment Currently available data are described in section 5.2, but no recommendation on a posology can be made. Paediatric population The safety and e� cacy of Lonquex in children and adolescents aged up to 17 years have not yet been established. Currently available data are described in sections 4.8, 5.1 and 5.2. Method of administration The solution is injected subcutaneously (SC). The injections should be given into the abdomen, upper arm or thigh. For instructions on handling of the medicinal product before administration, see section 6.6. Self-administration of Lonquex should only be performed by patients who are well motivated, adequately trained and have access to expert advice. The fi rst injection of Lonquex should be performed under direct medical supervision. Contraindications: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Undesirable e� ects: Summary of the safety profi le The most frequent undesirable e� ects are musculoskeletal pains. Musculoskeletal pains are generally of mild to moderate severity, transient and can be controlled in most patients with standard analgesics. Capillary leak syndrome, which can be life-threatening if treatment is delayed, has been reported mostly in cancer patients undergoing chemotherapy after administration of G-CSF or derivatives (see section  4.4 and subsection “Description of selected adverse reactions” of section 4.8). Tabulated list of adverse reactions The safety of lipegfi lgrastim has been evaluated based on results from clinical studies including 506 patients and 76 healthy volunteers treated at least once with lipegfi lgrastim. The adverse reactions listed below in table 1 are classifi ed according to System organ class. Frequency groupings are defi ned according to the following convention: Very common: ≥ 1/10. Common: ≥ 1/100 to < 1/10. Uncommon: ≥ 1/1,000 to

<  1/100. Rare: ≥  1/10,000 to <  1/1,000. Very rare: <  1/10,000. Not known: cannot be estimated from the available data. Within each frequency grouping, undesirable e� ects are presented in order of decreasing seriousness. Table 1: Adverse reactions Blood and lymphatic system disorders: Common: Thrombocytopenia*. Uncommon: Leukocytosis*, Splenomegaly*. Immune system disorders: Uncommon: Hypersensitivity reactions*. Metabolism and nutrition disorders: Common: Hypokalaemia*. Nervous system disorders: Common: Headache. Vascular disorders: Not known: Capillary leak syndrome*. Respiratory, thoracic and mediastinal disorders: Uncommon: Pulmonary adverse reactions*. Skin and subcutaneous tissue disorders: Common: Skin reactions*. Uncommon: Injection site reactions*. Musculoskeletal and connective tissue disorders: Very common: Musculoskeletal pains*. General disorders and administration site conditions: Common: Chest pain. Investigations: Uncommon: Blood alkaline phosphatase increased*, Blood lactate dehydrogenase increased*. *See subsection “Description of selected adverse reactions” below. Description of selected adverse reactions Thrombocytopenia and leukocytosis have been reported (see section 4.4). Splenomegaly, generally asymptomatic, has been reported (see section 4.4). Hypersensitivity reactions such as allergic skin reactions, urticaria, angioedema and serious allergic reactions may occur. Hypokalaemia has been reported (see section 4.4). Pulmonary adverse reactions, in particular interstitial pneumonia, have been reported (see section 4.4). These pulmonary adverse reactions may also include pulmonary oedema, pulmonary infi ltrates, pulmonary fi brosis, respiratory failure or ARDS (see section 4.4). Skin reactions such as erythema and rash may occur. Injection site reactions such as injection site induration and injection site pain may occur. The most frequent adverse reactions are musculoskeletal pains such as bone pain and myalgia. Musculoskeletal pains are generally of mild to moderate severity, transient and can be controlled in most patients with standard analgesics. Reversible, mild to moderate elevations in alkaline phosphatase and lactate dehydrogenase may occur, with no associated clinical e� ects. Elevations in alkaline phosphatase and lactate dehydrogenase most likely originate from the increase in neutrophils. Certain adverse reactions have not yet been observed with lipegfi lgrastim, but are generally accepted as being attributable to G-CSF and derivatives: Blood and lymphatic system disorders - Splenic rupture including some fatal cases (see section 4.4). - Sickle cell crisis in patients with sickle cell anaemia (see section 4.4). Vascular disorders - Capillary leak syndrome Cases of capillary leak syndrome have been reported in postmarketing experience after administration of G-CSF or derivatives. These have generally occurred in patients su� ering from advanced malignant diseases, having sepsis, taking multiple chemotherapy medications or undergoing apheresis (see section  4.4). Skin and subcutaneous tissue disorders - Acute febrile neutrophilic dermatosis (Sweet’s syndrome) - Cutaneous vasculitis. Paediatric population The experience in children is limited to a single-dose phase 1 study in 21 paediatric patients aged 2 to <18 years (see section 5.1), which did not indicate a di� erence in the safety profi le of lipegfi lgrastim in children compared to that in adults. Treatment-related adverse events were back pain, bone pain and increased neutrophil count (1  event each). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefi t/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions in Belgium via Federaal agentschap voor geneesmiddelen en gezondheidsproducten - Afdeling Vigilantie - EUROSTATION II - Victor Hortaplein, 40/40 - B-1060 Brussel - Website: www.fagg.be - e-mail: adversedrugreactions@fagg-afmps.be, and in Luxemburg via Direction de la Santé – Division de la Pharmacie et des Médicaments, Villa Louvigny – Allée Marconi, L-2120 Luxembourg - Website: http://www.ms.public.lu/fr/activites/pharmacie-medicament/index.html. MARKETING AUTHORISATION HOLDER: UAB “Sicor Biotech” Molėtų pl. 5 LT-08409 Vilnius Lithuania. MARKETING AUTHORISATION NUMBER(S): EU/1/13/856/001 - EU/1/13/856/002. DELIVERY: on medical prescription. DATE OF REVISION OF THE TEXT: 06/2016. Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.

Specialty MedicinesSpecialty Medicines

BE/

LNQ

X/1

6/0

042

/Tev

aPha

rma/

08.

2016

TEV 0245 ADV ENG DEF 01.indd 1 18/08/16 09:59

18 19

NOTESNOTES NOTESNOTES

20

Roche Oncology

R. E

.: D

r. C

hr. L

enae

rts -

BE

/ON

CO

/121

6/00

59 -

23/1

2/20

16

Power to prolong survival

®

t

® t

t

tt

t

NOTES

®

Sprycel Hospital Price

100 mg (30 tabs) € 3867,16

70 mg (60 tabs) € 4119,41

50 mg (60 tabs) € 4119,41

20 mg (60 tabs) € 2003,78

Approval date: 12/2015 - 729BE15PR14696-01

SPRY 6006 Annonce Sprycel A5.indd 1 20/12/16 16:16